InflaRx N.V. (IFRX) stock
IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.11−0.04 (-3.48%)
Close on Nov 18, 2026Market cap $80.25MP/E –Yield –
InflaRx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2023 it was -€44.91M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -€44.91M | – |
| FY2022 | Dec 31, 2022 | -€32.24M | – |
| FY2021 | Dec 31, 2021 | -€47.63M | – |
See a number that looks wrong?